Skip to main content
Premium Trial:

Request an Annual Quote

RXi Initiates Third Phase IIa Trial of Anti-scarring Drug

Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced that it has started a third Phase IIa trial for its anti-scarring treatment RXI-109.

RXI-109 is composed of siRNAs designed to inhibit connective tissue growth factor — a protein linked to wound healing and other fibrotic processes. It incorporates a proprietary self-delivering technology that enables cellular uptake of the RNAi molecules without the need for a delivery vehicle.

The drug is already in two Phase IIa studies — on comparing it against placebo in healthy subjects who undergo an elective surgical revision of a transverse hypertrophic scar on their abdomen and another in healthy subjects who undergo an elective keloid excision.

In the newly announced trial, RXI-109 will be tested in patients undergoing scar revision surgery for either a single scar or two scars comparable in length, anatomical location, and characteristics.

"For a single scar, a portion of the revised scar segment will be treated with RXI-109 and a comparably sized length on the opposite end of the excised scar segment will be left untreated," RXi said. "If two scars are revised, a portion of one revised scar segment will be treated with RXI-109 and one scar will be left untreated after revision surgery."

Patients will be followed for nine months.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.